Key Speakers
• Stephen Minger, Senior Lecturer in Stem Cell Biology, King’s College London
• Jan Lundberg, Executive Vice President - Discovery Research, AstraZeneca
• John Connolly, Head of Cell & Gene Therapies, Department of Health
• Alan Lamont, Director of Science and Technology Alliances, AstraZeneca
 • Robert Pinnock, Director, Scientific & Academic Liaison United Kingdom and Ireland, Merck Sharp & Dohme
• Paulo Fontoura, Translational Medicine Leader, F. Hoffmann-La Roche
• James Lawford Davies, Senior Partner, Clifford Chance
• Alexander Denoon, Senior Associate, Clifford Chance
• Jane Lebkowski, Chief Scientific Officer Regenerative medicine, Geron
• Rosemary Drake, Chief Scientific Officer, The Automation Partnership
• Lars Wahlberg, Executive Vice President & Chief Operating Officer, NsGene
• Anthony Hollander, Chief Scientific Officer, Azellon
• Robert Lechler, Vice Principal (Health), King’s College London
• Anthony Mathur, Senior Lecturer and Consultant Cardiologist, Barts and the London
• Robert Gaspar, Professor of Paediatrics and Immunology, Great Ormond Street Hospital

Set to more than quadruple from $48 to $208bn over the next 15 years, the global regenerative medicine market is set for stellar growth as therapies begin entering the clinic.

Regenerative medicine is set to revolutionise healthcare as stem cell, tissue engineering, gene therapy and materials science come together to transform patient treatment. Bringing you the latest in translational applications from leading experts, don’t miss this exceptional showcase of medical innovations in this fast-moving field.

By attending this conference you will gain the latest insights into:
• The economic future of the global regenerative medicine market and acquiring venture capital
• The use of stem cell therapies in type 1 diabetes
• Small molecule drugs to stimulate neurogenesis and neuroprotection in Parkinson’s disease
• The use of direct stem cell therapies in cardiovascular diseases
• The use of direct stem cell therapies in wound healing
• The use of direct stem cell therapies in bone remodelling
• Gene therapy for retinal degeneration
• Scaling-up in the lab
• Scaling up in manufacturing
• Clinical trials for novel therapies
• How to commercialise your product
• Overcoming patent, legal and regulatory hurdles

Who will be there?
Presidents, Chief Executive Officers, VPs, Chief Scientific Officers, Directors, Business Development Managers, and Principal Scientists of:
• Adult Stem Cell Research
• Embryonic Stem Cell Research
• Tissue Engineering
• Translational Medicine
• Gene Therapy
• Bioengineering and Bioprocessing
• Biotechnology
• Cell Therapy
• Biomaterials
• Neuroscience
• Diabetes
• Cardiovascular Medicine
• Pharmacology
• Pharmacogenomics
• Proteomics
• Personalised Medicine
• Business Development
• Strategic Alliances
• New Product Development
• Pharmacovigilance
• Process Development
• Manufacturing
• Clinical Trials
• Licensing and External Research